September 11, 2019
Stand Up To Cancer Hails Dr. Dennis J. Slamon, Pioneer In Modern Treatment of Breast Cancer and Leader SU2C Breast Cancer Dream Team
Stand Up To Cancer (SU2C) congratulates Dennis J. Slamon, MD, PhD, leader of the SU2C Breast Cancer Dream Team, on receiving the 2019 Lasker-DeBakey Clinical Medical Research Award for his development of Herceptin, a targeted treatment for HER2-positive breast cancer.
Read MoreAugust 5, 2019
STAND UP TO CANCER AND SOCIETY FOR IMMUNOTHERAPY OF CANCER ANNOUNCE POSTDOCTORAL CONVERGENCE SCHOLAR FELLOWSHIP AWARD RECIPIENTS
Read MoreJuly 1, 2019
Add A Name To A Plane: American Airlines Aims To Raise Valuable Funding For Stand Up To Cancer With Plane Naming Campaign
American Airlines will provide a once-in-a-lifetime opportunity to add a loved one’s name to one of its planes in honor of those who are cancer survivors, current cancer fighters and those who lost their battle with cancer.
Read MoreJune 12, 2019
Drs. Carpten and Pettigrew Are Named to Stand Up To Cancer Scientific Advisory Committee
Stand Up To Cancer (SU2C) with its Scientific Partner, the American Association for Cancer Research (AACR), announced two new members of the SU2C Scientific Advisory Committee (SAC): John D. Carpten, PhD, director of the Institute of Translational Genomics at the Keck School of Medicine of the University of Southern California (USC), and Roderic I. Pettigrew, PhD, MD, chief executive officer of Engineering Health (EnHealth) and executive dean for Engineering Medicine (EnMed), at Texas A&M University.
Read MoreJune 11, 2019
Stand Up To Cancer Hails FDA Approval of ALPELISIB + FULVESTRANT Combination For Patients With A PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer
Stand Up To Cancer (SU2C) welcomed the recent Food and Drug Administration (FDA) approval of alpelisib in combination with fulvestrant, the first and only new therapy for a difficult to treat form of advanced or metastatic breast cancer in both post-menopausal women and in men.
Read MoreMay 30, 2019
Stand Up To Cancer – Funded Research To Be Presented At ASCO Annual Meeting May 31 – June 4 in Chicago
Researchers whose work has been supported by Stand Up To Cancer, including Uri Tabori, MD, Hospital for Sick Children, Toronto, and Nabil M. Ahmed, MD, Baylor College of Medicine, will discuss their work in advancing immunotherapy for pediatric brain tumors at the Annual Meeting 2019 of the American Society of Clinical Oncology May 31-June 4 at McCormick Place in Chicago.
Read MoreMay 2, 2019
“Innovation in Collaboration” among Research Teams Rewarded by Grants from Stand Up To Cancer
Stand Up To Cancer (SU2C) announced five new awards today drawing on the strengths of existing research activities to explore cross-cutting questions that have the potential of opening new paths to improved cancer treatment, according to the American Association for Cancer Research, SU2C’s Scientific Partner.
Read MoreApril 18, 2019
Stand Up To Cancer, Mastercard & Marvel Studios’ Avengers: Endgame Unite To Help Take Down One Of The Biggest Villains Of All: Cancer
Stand Up To Cancer (SU2C), Mastercard and Marvel Studios’ Avengers: Endgame announced today that they are teaming up to take down one of the biggest villains of all, cancer, with an impactful new Public Service Announcement scheduled to launch in April.
Read MoreApril 17, 2019
Key Protein A Possible New Target in the Treatment of Pancreatic Cancer Pancreatic Cancer Collective Supports Important Study Published in Nature
Research funded by the Pancreatic Cancer Collective, a partnership between Lustgarten Foundation and Stand Up To Cancer and guided by Dr. Tony Hunter at the Salk Institute was published today in Nature and has found that the interaction between pancreatic stellate cells (PSC’s) and pancreatic cancer cells could be “exploitable” due to the presence of a key protein and lead to the development of new targeted strategies for pancreatic cancer therapy.
Read MoreMarch 31, 2019
Stand Up To Cancer Supported Clinical Trials Seeking To Extend CAR T-cell Therapy to Solid Tumors, Reported at AACR Annual Meeting
Stand Up To Cancer (SU2C) is helping scientists make progress in one of the most important areas of cancer research today: expanding the use of autologous CAR T-cell immunotherapy beyond leukemia and other blood cancers to solid tumors such as osteosarcoma and mesothelioma. If ultimately successful, the research could pave the way for a dramatic expansion of a therapy that has revolutionized treatment of blood malignancies but thus far, has had little impact on the solid tumors that make up most cancer cases.
Read More